ALXN - Alexion Pharmaceuticals Partners With Caelum Biosciences To Tackle Light Chain Amyloidosis
Introduction to Alexion Pharmaceuticals
Alexion Pharmaceuticals (ALXN) has been one of the greatest growth stories in the ultra-rare disease space over the past decade, with their blockbuster C5 inhibitor, Soliris, growing sales to nearly $4 billion in 2018. Although the company still managed to grow top-line revenue by more than 19% in 2018 (without any price increases), market share in their lead indications of PNH and aHUS is becoming somewhat saturated, and they are looking for new growth avenues.
The new management team put in place in early 2017, led by CEO Ludwig